• Avantor recently announced that its NuSil brand has expanded its collaboration with the Population Council to support development of a new three-month dapivirine vaginal ring for HIV prevention, building on NuSil’s prior role supplying ultra-high-purity silicones for the already-approved one-month ring used by women in multiple sub-Saharan African countries.
• The three-month ring, now under review by the European Medicines Agency, could meaningfully improve adherence and affordability by reducing annual replacements while relying on NuSil’s medical-grade silicones to sustain consistent drug release and mechanical performance over an extended period.
• Next, we’ll examine how Avantor’s role in supplying critical silicones for this three-month HIV-prevention ring might influence its broader investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

Avantor Investment Narrative Recap

To own Avantor, you need to believe it can turn a flat, margin-pressured lab and bioprocessing platform into a steadily profitable, cash-generating business while managing high leverage and a tough competitive backdrop. The NuSil collaboration on a three-month HIV-prevention ring highlights the depth of Avantor’s specialty materials know-how, but it does not materially change the near term story, which is still dominated by weak organic growth guidance, margin pressure, and balance sheet risk.

Among recent updates, Q1 2026 results were especially relevant: revenue was flat year over year at US$1,581.4 million while net income fell to US$43.3 million. This underscores how product wins like NuSil’s extended-duration ring are arriving against a backdrop of muted top line momentum and compressed profitability, keeping execution on cost controls and mix improvement front and center as investors weigh whether specialized materials contributions can meaningfully offset broader headwinds.

Yet in contrast, investors should be aware that margin pressure from aggressive pricing and upfront rebates could still undermine even the most promising product wins...

Avantor's narrative projects $6.9 billion revenue and $566.4 million earnings by 2029. This requires 1.8% yearly revenue growth and a $1,117.8 million earnings increase from -$551.4 million today.

Uncover how Avantor's forecasts yield a $10.31 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already expecting only about 1.3% annual revenue growth and US$425.0 million of earnings by 2029, a much more pessimistic view than consensus, so this NuSil HIV ring news and the risk of structurally lower margins give you a good reason to compare several viewpoints before deciding what you think is realistic.

Explore 2 other fair value estimates on Avantor - why the stock might be worth as much as 38% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Avantor research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Avantor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Avantor's overall financial health at a glance.

No Opportunity In Avantor?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.